Trial of Hypofractionated Intensity Modulated Radiation Therapy With Temozolomide and Granulocyte-macrophage Colony-stimulating Factor for Patients With Newly Diagnosed Glioblastoma Multiforme

Phase II Trial of Hypofractionated Intensity Modulated Radiation Therapy(IMRT) With Temozolomide and Granulocyte-macrophage Colony-stimulating Factor(GM-CSF) for Patients With Newly Diagnosed Glioblastoma Multiforme.

Inclusion Criteria:

• Newly diagnosed and pathologically confirmed glioblastoma multiforme without an enhanced lesion beside the cerebrospinal fluid space on baseline magnetic resonance imaging
• Karnofsky performance status more than 60
• Normal liver, kidney, and bone marrow function.

Exclusion Criteria:

• Previous allergies to granulocyte macrophage colony stimulating factor
• Receiving radiotherapy
• Receiving other investigational agents
• Had uncontrolled intercurrent illnesses.